{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:23Z","timestamp":1790369963204,"version":"4.1.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00520-026-11110-1","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:20:45Z","timestamp":1787210445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inverse dose proportionality: using breakthrough pain medication as a biological indicator for background analgesia escalation"],"prefix":"10.1007","volume":"34","author":[{"given":"Sebastiano","family":"Mercadante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Massimo","family":"Bellavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Lo Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"11110_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40265-021-01466-5","volume":"81","author":"S Mercadante","year":"2021","unstructured":"Mercadante S, Portenoy RK (2021) Understanding the chameleonic breakthrough cancer pain. Drugs 81:411\u2013418","journal-title":"Drugs"},{"key":"11110_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ejpain.2008.06.014","volume":"13","author":"AN Davies","year":"2009","unstructured":"Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331\u2013338","journal-title":"Eur J Pain"},{"key":"11110_CR3","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1185\/03007995.2013.837816","volume":"29","author":"GH Hans","year":"2013","unstructured":"Hans GH (2013) Treatment of breakthrough cancer pain: to titrate or to proportionate? Curr Med Res Opin 29:1523\u20131526","journal-title":"Curr Med Res Opin"},{"key":"11110_CR4","doi-asserted-by":"publisher","first-page":"e1159","DOI":"10.1097\/MD.0000000000011593","volume":"97","author":"TY Yen","year":"2018","unstructured":"Yen TY, Chiou JF, Chiang WY, Su WH, Huang MY, Hu MH, Wu SC, Lai YL (2018) Proportional dose of rapid-onset opioid in breakthrough cancer pain management: an open-label, multicenter study. Med (Baltimore) 97:e1159","journal-title":"Med (Baltimore)"},{"key":"11110_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1185\/03007995.2012.683112","volume":"28","author":"S Mercadante","year":"2012","unstructured":"Mercadante S, Gatti A, Porzio G, Lo Presti C, Aielli F, Adile C, Casuccio A (2012) Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin 28:963\u2013968","journal-title":"Curr Med Res Opin"},{"key":"11110_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ejp.1339","volume":"23","author":"S Mercadante","year":"2019","unstructured":"Mercadante S, Adile C, Masedu F, Marchetti P, Costanzi A, Aielli F (2019) Factors influencing the use of opioids for breakthrough cancer pain: a secondary analysis of the IOPS-MS study. Eur J Pain 23:719\u2013726","journal-title":"Eur J Pain"},{"key":"11110_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jpainsymman.2010.12.010","volume":"42","author":"S Mercadante","year":"2011","unstructured":"Mercadante S, Ferrera P, Adile C, Casuccio A (2011) Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage 42:464\u2013469","journal-title":"J Pain Symptom Manage"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11110-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:03:18Z","timestamp":1790366598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11110-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":7,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["11110"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11110-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and with applicable regulations on the protection of personal data and patient confidentiality. All consents and clinical data were processed anonymously and aggregated to ensure the privacy and confidentiality of the patients included in the analysis. The study protocol was reviewed and approved by the Local Ethics Committee of Palermo 1 (OSPTH VRS 1 06\/06\/2024).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"879"}}